14 results on '"Roberto Depascale"'
Search Results
2. Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study
- Author
-
Chiara Tani, Chiara Cardelli, Roberto Depascale, Anna Gamba, Luca Iaccarino, Andrea Doria, Matilde Bandeira, Sara Paiva Dinis, Vasco C. Romão, Emanuele Gotelli, Sabrina Paolino, Maurizio Cutolo, Niccolò Di Giosaffatte, Alessandro Ferraris, Paola Grammatico, Lorenzo Cavagna, Veronica Codullo, Carlomaurizio Montecucco, Valentina Longo, Lorenzo Beretta, Ilaria Cavazzana, Micaela Fredi, Silvia Peretti, Serena Guiducci, Marco Matucci-Cerinic, Stefano Bombardieri, Gerd R. Burmester, João E. Fonseca, Charissa Frank, Ilaria Galetti, Eric Hachulla, Ulf Müller-Ladner, Matthias Schneider, Vanessa Smith, Farah Tamirou, Jacob M. Van Laar, Ana Vieira, Rossella D'Urzo, Sara Cannizzo, Andrea Gaglioti, Diana Marinello, Rosaria Talarico, and Marta Mosca
- Subjects
ystemic autoimmune disease ,SARS-CoV-2 ,COVID-19 ,Vaccination ,Flare ,Breakthrough infection ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Background: Vaccination is one of the most important measures to contain the COVID-19 pandemic, especially for frail patients. VACCINATE is a multicentre prospective observational study promoted by the European Reference Network on Rare and Complex Connective Tissue and Musculoskeletal Diseases (ERN ReCONNET) aimed at assessing the long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases (rcCTDs) in terms of efficacy and safety. Methods: Adult rcCTDs patients were eligible for recruitment. Demographic, clinical and vaccination data were collected at enrolment. Follow-up visits were scheduled 4, 12, 24, 36 and 48 weeks after completion of the first vaccination cycle; data on adverse events, disease exacerbations and the occurrence of new SARS-CoV-2 infections were collected at these time-points. Findings: 365 rcCTDs patients (87 % female, mean age 51.8 ± 14.6 years) were recruited. Overall, 200 patients (54.8 %) experienced at least one adverse event, generally mild and in most cases occurring early after the vaccination. During follow-up, 55 disease exacerbations were recorded in 39 patients (10.7 %), distributed over the entire observation period, although most frequently within 4 weeks after completion of the vaccination cycle. The incidence of new SARS-CoV-2 infections was 8.9 per 1000 person-months, with no cases within 12 weeks from vaccine administration and an increasing trend of infections moving away from the primary vaccination cycle. Only one case of severe COVID-19 was reported during the study period. Interpretation: COVID-19 vaccination seems effective and safe in rcCTDs patients. The rate of new infections was rather low and serious infections were uncommon in our cohort. No increased risk of disease flares was observed compared to previous disease history; however, such exacerbations may be potentially severe, emphasising the need for close monitoring of our patients.
- Published
- 2023
- Full Text
- View/download PDF
3. CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies
- Author
-
Elisabetta Zanatta, Andrea Martini, Roberto Depascale, Anna Gamba, Marta Tonello, Mariele Gatto, Chiara Giraudo, Elisabetta Balestro, Andrea Doria, and Luca Iaccarino
- Subjects
interstitial lung disease (ILD) ,idiopathic inflammatory myopathies (IIMs) ,biomarkers ,autoantibodies ,progressive pulmonary fibrosis ,Medicine (General) ,R5-920 - Abstract
Objectives. To assess CCL18 and OX40L as biomarkers of interstitial lung disease (ILD) and/or progressive fibrosing (PF-) ILD in idiopathic inflammatory myopathies (IIMs). Methods. Patients with IIMs seen in our center from July 2020 to March 2021 were consecutively enrolled. ILD was detected by high-resolution CT. CCL18 and OX40L serum levels were measured by validated ELISA assays in 93 patients and 35 controls. At the 2-year follow-up, PF-ILD was evaluated according to the INBUILD criteria. Results. ILD was diagnosed in 50 (53.7%) patients. CCL18 serum levels were higher in IIMs patients vs. controls (232.9 [IQR 134.7–399.07] vs. 48.4 [29.9–147.5], p < 0.0001), with no difference for OX40L. IIMs-ILD patients exhibited higher levels of CCL18 than those without ILD (306.8 [190.8–520.5] vs. 162 [75.4–255.8], p < 0.0001). High CCL18 serum levels were independently associated with IIMs-ILD diagnosis. At follow-up, 22/50 (44%) patients developed a PF-ILD. Patients who developed PF-ILD had higher CCL18 serum levels than non-progressors (511 [307–958.7] vs. 207.1 [149.3–381.7], p < 0.0001). Multivariate logistic regression analysis revealed CCL18 as the only independent predictor of PF-ILD (OR 1.006 [1.002–1.011], p = 0.005). Conclusions. Although in a relatively small sample, our data suggest that CCL18 is a useful biomarker in IIMs-ILD, particularly in the early identification of patients at risk of developing PF-ILD.
- Published
- 2023
- Full Text
- View/download PDF
4. Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review
- Author
-
Roberto Depascale, Giulia Del Frate, Michela Gasparotto, Valeria Manfrè, Mariele Gatto, Luca Iaccarino, Luca Quartuccio, Salvatore De Vita, and Andrea Doria
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Lung involvement in systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) has extensively been outlined with a multiplicity of different manifestations. In SLE, the most frequent finding is pleural effusion, while in pSS, airway disease and parenchymal disorders prevail. In both cases, there is an increased risk of pre-capillary and post-capillary pulmonary arterial hypertension (PAH) and pulmonary venous thromboembolism (VTE). The risk of VTE is in part due to an increased thrombophilic status secondary to systemic inflammation or to the well-established association with antiphospholipid antibody syndrome (APS). The lung can also be the site of an organ-specific complication due to the aberrant pathologic immune-hyperactivation as occurs in the development of lymphoma or amyloidosis in pSS. Respiratory infections are a major issue to be addressed when approaching the differential diagnosis, and their exclusion is required to safely start an immunosuppressive therapy. Treatment strategy is mainly based on glucocorticoids (GCs) and immunosuppressants, with a variable response according to the primary pathologic process. Anticoagulation is recommended in case of VTE and multi-targeted treatment regimens including different drugs are the mainstay for PAH management. Antibiotics and respiratory physiotherapy can be considered relevant complement therapeutic measures. In this article, we reviewed lung manifestations in SLE and pSS with the aim to provide a comprehensive overview of their diagnosis and management to physicians taking care of patients with connective tissue diseases.
- Published
- 2021
- Full Text
- View/download PDF
5. Serum Biomarkers in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension
- Author
-
Beatrice Moccaldi, Laura De Michieli, Marco Binda, Giulia Famoso, Roberto Depascale, Martina Perazzolo Marra, Andrea Doria, and Elisabetta Zanatta
- Subjects
Inorganic Chemistry ,biomarkers ,connective tissue disease ,pathogenesis ,pulmonary arterial hypertension ,Organic Chemistry ,General Medicine ,Physical and Theoretical Chemistry ,Molecular Biology ,Spectroscopy ,Catalysis ,Computer Science Applications - Abstract
Pulmonary arterial hypertension (PAH) is a life-threatening complication of connective tissue diseases (CTDs) characterised by increased pulmonary arterial pressure and pulmonary vascular resistance. CTD-PAH is the result of a complex interplay among endothelial dysfunction and vascular remodelling, autoimmunity and inflammatory changes, ultimately leading to right heart dysfunction and failure. Due to the non-specific nature of the early symptoms and the lack of consensus on screening strategies—except for systemic sclerosis, with a yearly transthoracic echocardiography as recommended—CTD-PAH is often diagnosed at an advanced stage, when the pulmonary vessels are irreversibly damaged. According to the current guidelines, right heart catheterisation is the gold standard for the diagnosis of PAH; however, this technique is invasive, and may not be available in non-referral centres. Hence, there is a need for non-invasive tools to improve the early diagnosis and disease monitoring of CTD-PAH. Novel serum biomarkers may be an effective solution to this issue, as their detection is non-invasive, has a low cost and is reproducible. Our review aims to describe some of the most promising circulating biomarkers of CTD-PAH, classified according to their role in the pathophysiology of the disease.
- Published
- 2023
6. Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study—Joint and Skin (BeRLiSS-JS)
- Author
-
Margherita Zen, Mariele Gatto, Roberto Depascale, Francesca Regola, Micaela Fredi, Laura Andreoli, Franco Franceschini, Maria Letizia Urban, Giacomo Emmi, Fulvia Ceccarelli, Fabrizio Conti, Alessandra Bortoluzzi, Marcello Govoni, Chiara Tani, Marta Mosca, Tania Ubiali, Maria Gerosa, Enrica P. Bozzolo, Valentina Canti, Paolo Cardinaletti, Armando Gabrielli, Giacomo Tanti, Elisa Gremese, Ginevra De Marchi, Salvatore De Vita, Serena Fasano, Francesco Ciccia, Giulia Pazzola, Carlo Salvarani, Simone Negrini, Andrea Di Matteo, Rossella De Angelis, Giovanni Orsolini, Maurizio Rossini, Paola Faggioli, Antonella Laria, Matteo Piga, Alberto Cauli, Salvatore Scarpato, Francesca Wanda Rossi, Amato De Paulis, Enrico Brunetta, Angela Ceribelli, Carlo Selmi, Marcella Prete, Vito Racanelli, Angelo Vacca, Elena Bartoloni, Roberto Gerli, Elisabetta Zanatta, Maddalena Larosa, Francesca Saccon, Andrea Doria, Luca Iaccarino, Zen, Margherita, Gatto, Mariele, Depascale, Roberto, Regola, Francesca, Fredi, Micaela, Andreoli, Laura, Franceschini, Franco, Letizia Urban, Maria, Emmi, Giacomo, Ceccarelli, Fulvia, Conti, Fabrizio, Bortoluzzi, Alessandra, Govoni, Marcello, Tani, Chiara, Mosca, Marta, Ubiali, Tania, Gerosa, Maria, Bozzolo, Enrica P., Canti, Valentina, Cardinaletti, Paolo, Gabrielli, Armando, Tanti, Giacomo, Gremese, Elisa, De Marchi, Ginevra, De Vita, Salvatore, Fasano, Serena, Ciccia, Francesco, Pazzola, Giulia, Salvarani, Carlo, Negrini, Simone, Di Matteo, Andrea, DE ANGELIS, Rossella, Orsolini, Giovanni, Rossini, Maurizio, Faggioli, Paola, Laria, Antonella, Piga, Matteo, Cauli, Alberto, Scarpato, Salvatore, Wanda Rossi, Francesca, De Paulis, Amato, Brunetta, Enrico, Ceribelli, Angela, Selmi, Carlo, Prete, Marcella, Racanelli, Vito, Vacca, Angelo, Bartoloni, Elena, Gerli, Roberto, Zanatta, Elisabetta, Larosa, Maddalena, Saccon, Francesca, Doria, Andrea, and Iaccarino, Luca
- Subjects
disease activity score (DAS)-28 ,low disease activity ,remission ,systemic lupus erythematosus ,belimumab ,Cutaneous LE Area and Severity Index (CLASI) ,Medicine (miscellaneous) - Abstract
Aim. To assess the efficacy of belimumab in joint and skin manifestations in a nationwide cohort of patients with SLE. Methods. All patients with skin and joint involvement enrolled in the BeRLiSS cohort were considered. Belimumab (intravenous, 10 mg/kg) effectiveness in joint and skin manifestations was assessed by DAS28 and CLASI, respectively. Attainment and predictors of DAS28 remission (
- Published
- 2023
7. Kidney Involvement in Asia Syndrome: Case Report of an Uncommon Nephrotic Syndrome
- Author
-
Elena, Naso, Gianluca, Cuva, Roberto, Depascale, Angelini, Annalisa, Castellani, Chiara, Marny, Fedrigo, Calo', Lorenzo, and DEL PRETE, Dorella
- Subjects
Breast implant ,Nephrotic syndrome ,ASIA Syndrome - Published
- 2022
8. New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort
- Author
-
Michela Gasparotto, Sara Bindoli, Roberto Padoan, Giacomo Cozzi, Roberto Depascale, Elisabetta Zanatta, Alessandro Giollo, Mariele Gatto, Margherita Zen, Franco Schiavon, Roberta Ramonda, Paolo Sfriso, Andrea Doria, and Luca Iaccarino
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Abstract
Anti-COVID-19 vaccines have proved to be effective and well tolerated. Great attention is now being paid to the characterisation of possible adverse events associated to their administration. We report a case series of suspected rheumatic diseases (RDs) following anti-COVID-19 vaccination.We included patients evaluated at first-aid rheumatologic consultancy and at rheumatologic outpatient and inpatient clinic at Padova University Hospital between May and September 2021 presenting with a RD within 30 days after an anti-COVID-19 vaccine dose. Our selection was in accordance with the World Health Organisation guidelines for adverse event following immunisation (AEFI) surveillance. Patients were regularly re-evaluated by telemedicine or face-to-face visit.We identified 30 cases of RD following vaccination: 24 (80.0%) new onsets and 6 (20.0%) flares. Most of patients (76.6%) received the BNT162b2 vaccine. The mean time to RD onset/flare was 12±9 days. The most common manifestations were inflammatory arthritis (40.0%), rheumatic polymyalgia (33.3%) and adult-onset Still's disease (13.3%). At the last FU visit (9.6±2.2 months), 83.3% of patients showed complete response to first- or second-line therapy, 13.3% a partial response and one patient (3.3%) was still experiencing an active disease.Considering the amount of vaccine doses administered during the evaluation period we overall detected a limited number of cases. We noted a clear prevalence of autoinflammatory conditions and seronegative manifestations. The great majority of patients had mild features and showed a good response to therapy.
- Published
- 2021
9. Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review
- Author
-
Luca Iaccarino, Roberto Depascale, Luca Quartuccio, Valeria Manfrè, Giulia Del Frate, Andrea Doria, Salvatore De Vita, Michela Gasparotto, and Mariele Gatto
- Subjects
medicine.medical_specialty ,Pleural effusion ,Diseases of the musculoskeletal system ,Review ,Systemic inflammation ,primary Sjogren’s syndrome ,pulmonary involvement ,systemic inflammation ,systemic lupus erythematosus ,therapeutic strategies ,Rheumatology ,Internal medicine ,medicine ,Orthopedics and Sports Medicine ,Respiratory system ,Lung ,Interstitial Lung Disease in Autoimmune Rheumatic Disorders ,business.industry ,Amyloidosis ,medicine.disease ,Lymphoma ,medicine.anatomical_structure ,RC925-935 ,Differential diagnosis ,medicine.symptom ,Complication ,business - Abstract
Lung involvement in systemic lupus erythematosus (SLE) and primary Sjögren’s syndrome (pSS) has extensively been outlined with a multiplicity of different manifestations. In SLE, the most frequent finding is pleural effusion, while in pSS, airway disease and parenchymal disorders prevail. In both cases, there is an increased risk of pre-capillary and post-capillary pulmonary arterial hypertension (PAH) and pulmonary venous thromboembolism (VTE). The risk of VTE is in part due to an increased thrombophilic status secondary to systemic inflammation or to the well-established association with antiphospholipid antibody syndrome (APS). The lung can also be the site of an organ-specific complication due to the aberrant pathologic immune-hyperactivation as occurs in the development of lymphoma or amyloidosis in pSS. Respiratory infections are a major issue to be addressed when approaching the differential diagnosis, and their exclusion is required to safely start an immunosuppressive therapy. Treatment strategy is mainly based on glucocorticoids (GCs) and immunosuppressants, with a variable response according to the primary pathologic process. Anticoagulation is recommended in case of VTE and multi-targeted treatment regimens including different drugs are the mainstay for PAH management. Antibiotics and respiratory physiotherapy can be considered relevant complement therapeutic measures. In this article, we reviewed lung manifestations in SLE and pSS with the aim to provide a comprehensive overview of their diagnosis and management to physicians taking care of patients with connective tissue diseases.
- Published
- 2021
10. Belimumab: a step forward in the treatment of systemic lupus erythematosus
- Author
-
Roberto Depascale, Maddalena Larosa, Francesca Saccon, Mariele Gatto, Sara Bindoli, Andrea Doria, Elisabetta Zanatta, Luca Iaccarino, and Margherita Zen
- Subjects
0301 basic medicine ,Clinical Biochemistry ,B lymphocyte inhibition ,belimumab ,drug efficacy ,systemic lupus erythematosus ,Antibodies, Monoclonal, Humanized ,Efficacy ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,Drug Discovery ,medicine ,Humans ,Lupus Erythematosus, Systemic ,skin and connective tissue diseases ,Pharmacology ,Autoimmune disease ,B-Lymphocytes ,Biological Products ,business.industry ,food and beverages ,medicine.disease ,Belimumab ,030104 developmental biology ,030220 oncology & carcinogenesis ,Immunology ,business ,medicine.drug - Abstract
Introduction: Systemic Lupus Erythematosus (SLE) is a chronic B cell-mediated autoimmune disease which can potentially involve several organs and systems. The development of SLE is associated with ...
- Published
- 2021
11. Correction to: Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis
- Author
-
Margherita Zen, Enrico Fuzzi, Marta Loredo Martinez, Roberto Depascale, Micaela Fredi, Mariele Gatto, Maddalena Larosa, Francesca Saccon, Luca Iaccarino, and Andrea Doria
- Subjects
Rheumatology ,Pharmacology (medical) - Published
- 2022
12. Whipple’s aortitis
- Author
-
Roberto Depascale, Marco Pizzi, and Roberto Padoan
- Subjects
Aortitis ,Rheumatology ,Humans ,Pharmacology (medical) ,Whipple Disease - Published
- 2022
13. POS0755 PREVALENCE AND RELEVANCE OF ANTIBODIES AGAINST CITRULLINATED ALPHA ENOLASE (ANTI-CEP1) IN CONNECTIVE TISSUE DISEASES
- Author
-
Margherita Zen, F. Carubbi, E. Bartoloni Bocci, Alessia Alunno, M. Antonucci, Roberto Depascale, Onelia Bistoni, Roberto Gerli, Andrea Doria, Anna Ghirardello, and S. Calvacchi
- Subjects
Pathology ,medicine.medical_specialty ,biology ,Alpha-enolase ,business.industry ,Immunology ,Connective tissue ,General Biochemistry, Genetics and Molecular Biology ,medicine.anatomical_structure ,Rheumatology ,biology.protein ,medicine ,Immunology and Allergy ,Antibody ,business - Abstract
Background:Anti-citrullinated alpha enolase antibodies have been investigated in rheumatoid arthritis and associated with bone erosion and interstitial lung disease but little is known about their prevalence and role in connective tissue diseases (CTDs).Objectives:The aim of this study was to investigate the prevalence and relevance of anti-CEP1 antibodies in CTDs.Methods:Serum samples from five independent patient cohorts were assessed: 1) established (est) primary Sjogren’s syndrome (pSS) N=78, 2) est-systemic lupus erythematosus (SLE) N=52, 3) est-systemic sclerosis (SSc) N=71, 4) pSS at disease onset N=30, 5) SLE at disease onset N=46 (cohorts 4 and 5 had at least 3 years of follow-up). Samples from ninety sex and age matched healthy donors (HD) and 200 patients with est-RA (disease controls) were also tested. Anti-CEP1 IgG antibodies were measured with a commercially available ELISA kit (Euroimmun, Luebeck, Germany).Results:Anti-CEP1 titer was significantly higher in est-pSS, est-SLE and est-SSc compared to HD, significantly lower in est-pSS and est-SSc compared to est-RA and comparable in est-SLE versus est-RA. We divided patients in every CTD group based on whether their anti-CEP1 titer was below or above the 25th, 50th and 75th percentile. In est-SLE anti-CEP1 values over the 25th percentile were associated with articular involvement (odds ratio, OR (95% confidence interval, CI)=11.5; 1.9-70.6, p=0.008). In est-pSS, no relationship between anti-CEP1>25th percentile and articular involvement was found but rather an association with rheumatoid factor positivity (OR (95% CI)=4.8, 1.6-14.1, p=0.004) and salivary gland swelling (OR (95% CI)=6.2, 1.3-29.1, p=0.021). In est-SSc no difference could be detected across the 3 groups. Anti-CEP-1 titers in pSS and SLE at onset did not differ from each other, were comparable also to those of HD and significantly lower than those of est-pSS, est-SLE and est-RA patients (all pConclusion:Anti-CEP-1 antibodies can be detected in CTDs at different title during the disease course and may increase overtime, at least in pSS. Although anti-CEP1 antibodies are associated with specific clinical manifestation in est-CTDs, such as articular involvement in est-SLE, they seem to lack a predictive value for future manifestations when measured at disease onset.References:[1]Alunno A, Bistoni O, Pratesi F et al Rheumatology (Oxford) 2018.[2]Manca ML, Alunno A, D’Amato C et al. Joint Bone Spine 2018.Disclosure of Interests:None declared
- Published
- 2021
14. SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients
- Author
-
Francesco Benvenuti, Luca Iaccarino, Mara Felicetti, Francesca Saccon, Michela Gasparotto, Mariele Gatto, Mariagrazia Lorenzin, Margherita Zen, Augusta Ortolan, E. Fuzzi, D. Astorri, Paolo Sfriso, Elisabetta Zanatta, Maddalena Larosa, Giacomo Cozzi, Roberto Padoan, Sara Bindoli, L. Ienna, Franco Schiavon, Roberta Ramonda, D. Campaniello, Andrea Doria, and Roberto Depascale
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Cross-sectional study ,Pneumonia, Viral ,Immunology ,Population ,ANCA vasculitis ,Asymptomatic ,Article ,Autoimmune Diseases ,Betacoronavirus ,03 medical and health sciences ,Systemic lupus erythematosus ,0302 clinical medicine ,Rheumatic Diseases ,Internal medicine ,medicine ,Sore throat ,Humans ,Immunology and Allergy ,Rheumatoid arthritis ,skin and connective tissue diseases ,education ,Pandemics ,Aged ,030203 arthritis & rheumatology ,education.field_of_study ,SARS-CoV-2 ,business.industry ,Incidence (epidemiology) ,COVID-19 ,Middle Aged ,medicine.disease ,030104 developmental biology ,Italy ,Cohort ,Systemic sclerosis ,Female ,medicine.symptom ,Idiopathic inflammatory myopathies ,Coronavirus Infections ,business ,Vasculitis ,Immunosuppressive Agents - Abstract
Background Whether patients with autoimmune rheumatic diseases (ARD) have a higher risk for SARS-CoV-2 infection (COVID-19) and how SARS-CoV-2 pandemic impacts on adherence to therapy has not been fully elucidated. We assessed the rate and clinical presentation of COVID-19, and adherence to therapy in a large cohort of patients with ARD followed-up in a tertiary University-Hospital in Northeast Italy. Methods Between April 9th and April 25th, 2020, after SARS-CoV-2 infection peak, a telephone survey investigating the impact of COVID-19 on patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), rheumatoid arthritis (RA), ANCA-associated vasculitis (AAV), and idiopathic inflammatory myopathies (IIM) was administered. Demographics, disease activity status, therapy, occupational exposure, and adherence to social distancing advise were also collected. Results 916 patients (397 SLE, 182 AAV, 176 SSc, 111 RA, 50 IIM) completed the survey. 148 patients developed at least one symptom compatible with COVID-19 (cough 96, sore throat 64, fever 64, arthromyalgias 59, diarrhea 26, conjunctivitis 18, ageusia/hyposmia, 18). Among the 916 patients, 65 (7.1%) underwent SARS-CoV-2 nasopharyngeal swab (18 symptomatic and 47 asymptomatic), 2 (0.21%) tested positive, a proportion similar to that observed in the general population of the Veneto region. No deaths occurred. 31 patients (3.4%) withdrew ≥1 medication, mainly immunosuppressants or biologics. Adoption of social distancing was observed by 860 patients (93.9%), including 335 (36.6%) who adopted it before official lockdown. Conclusions COVID-19 incidence seems to be similar in our cohort compared to the general population. Adherence to therapy and to social distancing advise was high., Highlights • SARS-CoV-2 infection rate in ARDs seems to be similar to that of the general population. • Adoption of social distancing measures was prevalent among different ARD groups. • Earlier social distancing was more common in unremitted patients, treated with multiple drugs. • Therapy discontinuation due to COVID-related concerns was rare, but undertaken even by active patients. • Therapeutic regimens based on ≥3 drugs were associated with therapy discontinuation in our cohort.
- Published
- 2020
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.